DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells.
The DNA-damaging drug doxorubicin (Dox) induces cell senescence at concentrations significantly lower than those required for induction of apoptosis. At low Dox concentrations, tumor suppressor p53 is activated, which enhances the expression of p21(Waf1/Cip1) (p21). At high concentrations, Dox activates p53 leading to apoptosis without enhancing p21 expression. The underlying mechanisms and factors that govern the differential effects of Dox in inducing senescence and apoptosis are unclear. Here, we report that the DNA methyltransferase (DNMT) DNMT3a was upregulated by Dox especially at concentrations that induced apoptosis in HCT116 colorectal cancer cells, and this process was regulated by p53. Meanwhile, p21 expression was significantly upregulated at senescence-inducing concentrations and kept low on treatment with apoptosis-inducing concentrations of Dox. The differential expression of DNMT3a and p21 in response to Dox suggests that DNMT3a may be a key factor in switches between Dox-induced senescence and apoptosis. Moreover, when DNMT3a was silenced, treatment of HCT116 cells with apoptosis-inducing concentration of Dox increased the percentage of cells undergoing senescence, accompanied by upregulation of p21. Contrarily, senescence-inducing concentration of Dox promoted apoptosis rate, and p21 expression was repressed. Surprisingly, no changes in DNA methylation status at p21 promoter were detected at either ranges of Dox, although DNMT3a and HDAC1 were recruited to p21 promoter at apoptosis-inducing Dox concentration, where they were present in the same complex. Overall, these data demonstrate that DNMT3a impacts the expression of p21 and plays a role in determining the Dox-induced senescence and apoptosis in HCT116 cells.
Zhang
Yu
Y
The Institute of Genetics and Cytology, The Key Laboratory of Molecular Epigenetics of Ministry of Education, Northeast Normal University, Changchun, China.
Gao
Yanyan
Y
Zhang
Guoping
G
Huang
Shuyan
S
Dong
Zhixiong
Z
Kong
Chenfei
C
Su
Dongmei
D
Du
Juan
J
Zhu
Shan
S
Liang
Qian
Q
Zhang
Jianchao
J
Lu
Jun
J
Huang
Baiqu
B
D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D016922:Cellular Senescence / Q000187:drug effects*; D015179:Colorectal Neoplasms / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics* / Q000378:metabolism; D000090205:DNA Methyltransferase 3A; D017931:DNA Primers; D004317:Doxorubicin / Q000494:pharmacology*; D006801:Humans; D020287:In Situ Nick-End Labeling; D010957:Plasmids; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D015854:Up-Regulation
D017931:DNA Primers; C000717967:DNMT3A protein, human; D004317:Doxorubicin; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A